Green D, Hull RD, Brant R, et al. Lower mortality in cancer patients treated with low molecular weight versus standard heparin.Lancet1992;339:1476-1476.
2.
Siragusa S, Cosmi B, Piovella F, et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis. Am J Med1996;100:269-269.
3.
Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: A meta-analysis of randomized, controlled trials. Ann Intern Med1999;130:800-800.
4.
Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low molecular-weight heparin in small cell lung cancer. J Thromb Haemost2004;2:1266-1266.
5.
Lee AYY, Rickles FR, Julian JA, et al. A randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol2005;23:2123-2123.
6.
Klerk CPW, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol2005;23:2130-2130.
7.
Lemoine NR. Antithrombotic therapy in cancer. J Clin Oncol2005;23:2119-2119.
8.
Balkwill F. Cancer and chemokine network. Nat Rev Cancer2004;4:540-540.
9.
Muller A, Homey B, Soto, H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature2001;410:50-50.
10.
Cahalon L, Lider O, Schor H, et al. Heparin disaccharides inhibit tumor necrosis factor-α production by macrophages and arrest immune inflammation in rodents. Int Immunol1997;9:1517-1517.
11.
Hecht I, Hershkoviz R, Shivtiel S, et al. Heparin-disaccharide affects T cells: Inhibition of NF-kappaB activation, cell migration, and modulation of intracellular signaling. J Leukoc Biol2004;75:1139-1139.
12.
Harvey JR, Mellor P, Kirby JA, et al. Preventing breast cancer metastasis—heparins as inhibitors of chemokine function. Proc Am Assoc Cancer Res2005;46:abstract 5207-5207.
13.
Veldkamp CT, Peterson FC, Pelzek AJ, Volkman BF. The monomer-dimer equilibrium of stromal cell-derived factor-1 (CXCL12) is altered by pH, phosphate, sulfate, and heparin. Protein Sci2005;14:1071-1071.